AMGN · Amgen Inc.

Big-cap biotech; aging blockbusters plus the MariTide obesity bet

Risiko 4/10 · MODERATE RISK · leveraged big biotech · $437.23 ▼ 1.55%🤖Von KI geschrieben

Stand der Zahlen: 07.09.2026 · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

• Price $437.23
• Market cap $236.4B
• P/E (ttm) 27.17
• Div yield 2.31%
• 52-wk range $269.77 – $447.03
• Index rank #61 / #25

Wichtigste Risiken

• MariTide obesity data disappointing against Lilly and Novo (Shareholders) — HIGH
• Biosimilar erosion of legacy blockbuster revenue (Shareholders) — HIGH
• Acquisition debt limiting pipeline firepower (Bondholders) — MED
• US drug-pricing negotiation squeezing margins (Shareholders) — MED

Fazit

Fine as a yield-plus-pipeline holding, but with analyst targets below the price, the obesity bet now has to deliver.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.